Sandoz Group AG (SDZXF)
- Previous Close
44.94 - Open
45.23 - Bid 39.00 x 40000
- Ask 41.00 x 40000
- Day's Range
45.23 - 45.23 - 52 Week Range
31.84 - 49.83 - Volume
36 - Avg. Volume
1,482 - Market Cap (intraday)
16.492B - Beta (5Y Monthly) --
- PE Ratio (TTM)
∞ - EPS (TTM)
0.00 - Earnings Date Mar 5, 2025
- Forward Dividend & Yield 0.74 (1.87%)
- Ex-Dividend Date Apr 17, 2025
- 1y Target Est
48.31
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
www.sandoz.com22,049
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SDZXF
View MorePerformance Overview: SDZXF
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SDZXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SDZXF
View MoreValuation Measures
Market Cap
17.21B
Enterprise Value
20.87B
Trailing P/E
--
Forward P/E
9.86
PEG Ratio (5yr expected)
0.10
Price/Sales (ttm)
1.65
Price/Book (mrq)
2.08
Enterprise Value/Revenue
2.01
Enterprise Value/EBITDA
28.13
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
0.98%
Return on Equity (ttm)
0.01%
Revenue (ttm)
10.38B
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
0.00
Balance Sheet and Cash Flow
Total Cash (mrq)
1.19B
Total Debt/Equity (mrq)
59.64%
Levered Free Cash Flow (ttm)
632M